ARMD: Data of the Age-Related Macular Degeneration Study
In Surrogate: Evaluation of Surrogate Endpoints in Clinical Trials
ARMD R Documentation
Data of the Age-Related Macular Degeneration Study
Description
These are the data of a clinical trial involving patients suffering from age-related macular degeneration (ARMD), a condition that involves a progressive loss of vision. A total of 181 patients from 36 centers participated in the trial. Patients' visual acuity was assessed using standardized vision charts. There were two treatment conditions (placebo and interferon-\alpha). The potential surrogate endpoint is the change in the visual acuity at 24 weeks (6 months) after starting treatment. The true endpoint is the change in the visual acuity at 52 weeks.
Usage
data(ARMD)
Format
A data.frame with 181 observations on 5 variables.
IdThe Patient ID.
CenterThe center in which the patient was treated.
TreatThe treatment indicator, coded as -1 = placebo and 1 = interferon-\alpha.
Diff24The change in the visual acuity at 24 weeks after starting treatment. This endpoint is a potential surrogate for Diff52.
Diff52The change in the visual acuity at 52 weeks after starting treatment. This outcome serves as the true endpoint.
Surrogate documentation built on Sept. 25, 2023, 5:07 p.m.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
| ARMD | R Documentation |
Data of the Age-Related Macular Degeneration Study
Description
These are the data of a clinical trial involving patients suffering from age-related macular degeneration (ARMD), a condition that involves a progressive loss of vision. A total of 181 patients from 36 centers participated in the trial. Patients' visual acuity was assessed using standardized vision charts. There were two treatment conditions (placebo and interferon-\alpha). The potential surrogate endpoint is the change in the visual acuity at 24 weeks (6 months) after starting treatment. The true endpoint is the change in the visual acuity at 52 weeks.
Usage
data(ARMD)Format
A data.frame with 181 observations on 5 variables.
IdThe Patient ID.
CenterThe center in which the patient was treated.
TreatThe treatment indicator, coded as
-1= placebo and1= interferon-\alpha.Diff24The change in the visual acuity at
24weeks after starting treatment. This endpoint is a potential surrogate forDiff52.Diff52The change in the visual acuity at
52weeks after starting treatment. This outcome serves as the true endpoint.
R Package Documentation
Browse R Packages
We want your feedback!
Note that we can't provide technical support on individual packages. You should contact the package authors for that.
Embedding an R snippet on your website
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.